- Home
- JBGS vs MDXG Comparison
JBGS vs MDXG Comparison
Compare JBGS & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBGS | MDXG |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | JBGS | MDXG |
|---|---|---|
| Price | $16.56 | $5.16 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $18.00 | $10.67 |
| AVG Volume (30 Days) | 485.0K | ★ 1.2M |
| Earning Date | 02-17-2026 | 02-25-2026 |
| Dividend Yield | ★ 4.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $501,226,000.00 | $393,442,000.00 |
| Revenue This Year | N/A | $19.13 |
| Revenue Next Year | $1.79 | N/A |
| P/E Ratio | ★ N/A | $19.07 |
| Revenue Growth | N/A | ★ 14.77 |
| 52 Week Low | $13.28 | $4.89 |
| 52 Week High | $24.30 | $8.65 |
Technical Indicators
Market Signals| Indicator | JBGS | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 29.11 |
| Support Level | $16.31 | $4.89 |
| Resistance Level | $16.90 | $5.21 |
| Average True Range (ATR) | 0.44 | 0.17 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 27.27 | 34.82 |
Price Performance
Historical ComparisonAbout JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.